ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1209

Phospholipase A2 Group 5 Is a Potential Therapeutic Target for Osteoarthritis Treatment

Ming Liu1, Andrew Furey2, Weidong Zhang3, Sergei Likhodi2, Edward Randell2, Proton Rahman4 and Guangju Zhai2, 1Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Memorial University of Newfoundland, St. John's, NF, Canada, 3Jilin University, Changchun, China, 4Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cytokines, Gene Expression, osteoarthritis and phospholipase

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We recently discovered that lysophosphotidylcholines (lysoPCs) to phosphotidylcholines (PCs) ratio was associated with knee osteoarthritis (OA), suggesting that the conversion of PCs to lysoPCs catalyzed by phospholipases A2 (PLA2) was over activated. The aim of the study was to examine the gene expression levels of multiple PLA2 enzymes in human cartilage and identify the specific one that is important in OA.

Methods: Human cartilage samples were collected from patients undergoing total hip/knee joint replacement surgery due to primary OA or hip fractures as controls. RNA was extracted from the cartilage tissues. mRNA levels of three PLA2 enzymes, namely PLA2IIa, IVa, and V, and three cytokines, namely IL-6, IL-1β, and TNF-α were measured by real-time quantitative PCR (qPCR). Expression levels in each sample were calculated as fold changes in relation to the calibrator using Livak method.

Results: A total of 33 OA cases (24 hip OA and 9 knee OA) and 21 healthy controls were included. We found that PLA2V expression level was substantially increased by 445% in OA-affected cartilage compared to OA-free cartilage (p=0.003), but not PLA2IIa and PLA2IVa (p>0.05). Similarly, the expression level of TNF-α was significantly increased by 193% in OA-affected cartilage compared to the OA-free cartilage (p=0.007), but not IL-6 and IL-1β. Further, the expression level of PLA2V was highly correlated with TNF-α expression with a correlation coefficient of 0.71 (p<0.0001).

Conclusion: Our data indicated that inflammatory process was involved in OA and resulted in substantial over expression of PLA2V and excessive conversion of PCs to lysoPCs, suggesting PLA2V could be a novel therapeutic target for OA.


Disclosure: M. Liu, None; A. Furey, None; W. Zhang, None; S. Likhodi, None; E. Randell, None; P. Rahman, Janssen Pharmaceutica Product, L.P., 8,Amgen, AbbVie, BMS, Celgene, Pfizer, Janssen, Wyeth, EliLiiy, Novartis, 8,Amgen, AbbVie, BMS, Celgene, Pfizer, Janssen, Wyeth, EliLiiy, Novartis, 5; G. Zhai, None.

To cite this abstract in AMA style:

Liu M, Furey A, Zhang W, Likhodi S, Randell E, Rahman P, Zhai G. Phospholipase A2 Group 5 Is a Potential Therapeutic Target for Osteoarthritis Treatment [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/phospholipase-a2-group-5-is-a-potential-therapeutic-target-for-osteoarthritis-treatment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phospholipase-a2-group-5-is-a-potential-therapeutic-target-for-osteoarthritis-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology